Diagnostic markers of urothelial cancer based on DNA methylation analysis

Yoshitomo Chihara, Yae Kanai, Hiroyuki Fujimoto, Kokichi Sugano, Kiyotaka Kawashima, Gangning Liang, Peter A. Jones, Kiyohide Fujimoto, Hiroki Kuniyasu, Yoshihiko Hirao

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Early detection and risk assessment are crucial for treating urothelial cancer (UC), which is characterized by a high recurrence rate, and necessitates frequent and invasive monitoring. We aimed to establish diagnostic markers for UC based on DNA methylation. Methods: In this multi-center study, three independent sample sets were prepared. First, DNA methylation levels at CpG loci were measured in the training sets (tumor samples from 91 UC patients, corresponding normal-appearing tissue from these patients, and 12 normal tissues from age-matched bladder cancer-free patients) using the Illumina Golden Gate methylation assay to identify differentially methylated loci. Next, these methylated loci were validated by quantitative DNA methylation by pyrosequencing, using another cohort of tissue samples (Tissue validation set). Lastly, methylation of these markers was analyzed in the independent urine samples (Urine validation set). ROC analysis was performed to evaluate the diagnostic accuracy of these 12 selected markers. Results: Of the 1303 CpG sites, 158 were hyper ethylated and 356 were hypo ethylated in tumor tissues compared to normal tissues. In the panel analysis, 12 loci showed remarkable alterations between tumor and normal samples, with 94.3% sensitivity and 97.8% specificity. Similarly, corresponding normal tissue could be distinguished from normal tissues with 76.0% sensitivity and 100% specificity. Furthermore, the diagnostic accuracy for UC of these markers determined in urine samples was high, with 100% sensitivity and 100% specificity. Conclusion: Based on these preliminary findings, diagnostic markers based on differential DNA methylation at specific loci can be useful for non-invasive and reliable detection of UC and epigenetic field defect.

Original languageEnglish
Pages (from-to)275
Number of pages1
JournalBMC Cancer
DOIs
Publication statusAccepted/In press - 2013 Jun 4
Externally publishedYes

Fingerprint

DNA Methylation
Neoplasms
Urine
Sensitivity and Specificity
Methylation
Urinary Bladder Neoplasms
Epigenomics
ROC Curve
Recurrence

ASJC Scopus subject areas

  • Genetics
  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Chihara, Y., Kanai, Y., Fujimoto, H., Sugano, K., Kawashima, K., Liang, G., ... Hirao, Y. (Accepted/In press). Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer, 275. https://doi.org/10.1186/1471-2407-13-275

Diagnostic markers of urothelial cancer based on DNA methylation analysis. / Chihara, Yoshitomo; Kanai, Yae; Fujimoto, Hiroyuki; Sugano, Kokichi; Kawashima, Kiyotaka; Liang, Gangning; Jones, Peter A.; Fujimoto, Kiyohide; Kuniyasu, Hiroki; Hirao, Yoshihiko.

In: BMC Cancer, 04.06.2013, p. 275.

Research output: Contribution to journalArticle

Chihara, Y, Kanai, Y, Fujimoto, H, Sugano, K, Kawashima, K, Liang, G, Jones, PA, Fujimoto, K, Kuniyasu, H & Hirao, Y 2013, 'Diagnostic markers of urothelial cancer based on DNA methylation analysis', BMC Cancer, pp. 275. https://doi.org/10.1186/1471-2407-13-275
Chihara, Yoshitomo ; Kanai, Yae ; Fujimoto, Hiroyuki ; Sugano, Kokichi ; Kawashima, Kiyotaka ; Liang, Gangning ; Jones, Peter A. ; Fujimoto, Kiyohide ; Kuniyasu, Hiroki ; Hirao, Yoshihiko. / Diagnostic markers of urothelial cancer based on DNA methylation analysis. In: BMC Cancer. 2013 ; pp. 275.
@article{1379ddf0c7b14094acf677c9ea01d731,
title = "Diagnostic markers of urothelial cancer based on DNA methylation analysis",
abstract = "Background: Early detection and risk assessment are crucial for treating urothelial cancer (UC), which is characterized by a high recurrence rate, and necessitates frequent and invasive monitoring. We aimed to establish diagnostic markers for UC based on DNA methylation. Methods: In this multi-center study, three independent sample sets were prepared. First, DNA methylation levels at CpG loci were measured in the training sets (tumor samples from 91 UC patients, corresponding normal-appearing tissue from these patients, and 12 normal tissues from age-matched bladder cancer-free patients) using the Illumina Golden Gate methylation assay to identify differentially methylated loci. Next, these methylated loci were validated by quantitative DNA methylation by pyrosequencing, using another cohort of tissue samples (Tissue validation set). Lastly, methylation of these markers was analyzed in the independent urine samples (Urine validation set). ROC analysis was performed to evaluate the diagnostic accuracy of these 12 selected markers. Results: Of the 1303 CpG sites, 158 were hyper ethylated and 356 were hypo ethylated in tumor tissues compared to normal tissues. In the panel analysis, 12 loci showed remarkable alterations between tumor and normal samples, with 94.3{\%} sensitivity and 97.8{\%} specificity. Similarly, corresponding normal tissue could be distinguished from normal tissues with 76.0{\%} sensitivity and 100{\%} specificity. Furthermore, the diagnostic accuracy for UC of these markers determined in urine samples was high, with 100{\%} sensitivity and 100{\%} specificity. Conclusion: Based on these preliminary findings, diagnostic markers based on differential DNA methylation at specific loci can be useful for non-invasive and reliable detection of UC and epigenetic field defect.",
author = "Yoshitomo Chihara and Yae Kanai and Hiroyuki Fujimoto and Kokichi Sugano and Kiyotaka Kawashima and Gangning Liang and Jones, {Peter A.} and Kiyohide Fujimoto and Hiroki Kuniyasu and Yoshihiko Hirao",
year = "2013",
month = "6",
day = "4",
doi = "10.1186/1471-2407-13-275",
language = "English",
pages = "275",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Diagnostic markers of urothelial cancer based on DNA methylation analysis

AU - Chihara, Yoshitomo

AU - Kanai, Yae

AU - Fujimoto, Hiroyuki

AU - Sugano, Kokichi

AU - Kawashima, Kiyotaka

AU - Liang, Gangning

AU - Jones, Peter A.

AU - Fujimoto, Kiyohide

AU - Kuniyasu, Hiroki

AU - Hirao, Yoshihiko

PY - 2013/6/4

Y1 - 2013/6/4

N2 - Background: Early detection and risk assessment are crucial for treating urothelial cancer (UC), which is characterized by a high recurrence rate, and necessitates frequent and invasive monitoring. We aimed to establish diagnostic markers for UC based on DNA methylation. Methods: In this multi-center study, three independent sample sets were prepared. First, DNA methylation levels at CpG loci were measured in the training sets (tumor samples from 91 UC patients, corresponding normal-appearing tissue from these patients, and 12 normal tissues from age-matched bladder cancer-free patients) using the Illumina Golden Gate methylation assay to identify differentially methylated loci. Next, these methylated loci were validated by quantitative DNA methylation by pyrosequencing, using another cohort of tissue samples (Tissue validation set). Lastly, methylation of these markers was analyzed in the independent urine samples (Urine validation set). ROC analysis was performed to evaluate the diagnostic accuracy of these 12 selected markers. Results: Of the 1303 CpG sites, 158 were hyper ethylated and 356 were hypo ethylated in tumor tissues compared to normal tissues. In the panel analysis, 12 loci showed remarkable alterations between tumor and normal samples, with 94.3% sensitivity and 97.8% specificity. Similarly, corresponding normal tissue could be distinguished from normal tissues with 76.0% sensitivity and 100% specificity. Furthermore, the diagnostic accuracy for UC of these markers determined in urine samples was high, with 100% sensitivity and 100% specificity. Conclusion: Based on these preliminary findings, diagnostic markers based on differential DNA methylation at specific loci can be useful for non-invasive and reliable detection of UC and epigenetic field defect.

AB - Background: Early detection and risk assessment are crucial for treating urothelial cancer (UC), which is characterized by a high recurrence rate, and necessitates frequent and invasive monitoring. We aimed to establish diagnostic markers for UC based on DNA methylation. Methods: In this multi-center study, three independent sample sets were prepared. First, DNA methylation levels at CpG loci were measured in the training sets (tumor samples from 91 UC patients, corresponding normal-appearing tissue from these patients, and 12 normal tissues from age-matched bladder cancer-free patients) using the Illumina Golden Gate methylation assay to identify differentially methylated loci. Next, these methylated loci were validated by quantitative DNA methylation by pyrosequencing, using another cohort of tissue samples (Tissue validation set). Lastly, methylation of these markers was analyzed in the independent urine samples (Urine validation set). ROC analysis was performed to evaluate the diagnostic accuracy of these 12 selected markers. Results: Of the 1303 CpG sites, 158 were hyper ethylated and 356 were hypo ethylated in tumor tissues compared to normal tissues. In the panel analysis, 12 loci showed remarkable alterations between tumor and normal samples, with 94.3% sensitivity and 97.8% specificity. Similarly, corresponding normal tissue could be distinguished from normal tissues with 76.0% sensitivity and 100% specificity. Furthermore, the diagnostic accuracy for UC of these markers determined in urine samples was high, with 100% sensitivity and 100% specificity. Conclusion: Based on these preliminary findings, diagnostic markers based on differential DNA methylation at specific loci can be useful for non-invasive and reliable detection of UC and epigenetic field defect.

UR - http://www.scopus.com/inward/record.url?scp=84878405583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878405583&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-13-275

DO - 10.1186/1471-2407-13-275

M3 - Article

C2 - 23735005

AN - SCOPUS:84878405583

SP - 275

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

ER -